NYSE American · Biotechnology · USD
CEL-SCI Corporation (CVM) Stock Analysis
CEL-SCI Corporation (CVM) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CVM Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.56
- Previous Close
- $1.55
- Day's Range
- 1.51–1.62
- 52-Week Range
- 0.89–9.35
- Volume
- 149.41K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.59
Valuation
- Market Cap
- $28.49M
- P/E Ratio
- unprofitable
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 1.12
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.69
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$25.41M
- Shares Outstanding
- 17.59M
- 1-Year Return
- −82.41%
Dividend and dates
- Avg Volume
- 206.25K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CVM closed at $1.62, −82.41% over 1 year.
CEL-SCI Corporation (CVM) has a market capitalization of $28.49M.
In fiscal 2025, CVM reported revenue of $0.00.
CVM Stock Return by Calendar Year
CEL-SCI Corporation (CVM) 10-year return: what $10,000 became
- 1 year
- $10,000 $1,759
- −82.41%
- 5 years
- $10,000 $47
- −99.53%
- 10 years
- $10,000 $90
- −99.10%
If you had invested $10,000 in CEL-SCI Corporation (CVM) 10 years ago, at the close on October 21, 2016, it would have been worth $90 at the close on October 21, 2026: −99.10% in total, −37.57% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −69.20% |
| 2025 | −56.17% |
| 2024 | −85.29% |
| 2023 | +15.74% |
| 2022 | −66.90% |
| 2021 | −39.11% |
| 2020 | +27.43% |
| 2019 | +218.82% |
| 2018 | +51.85% |
| 2017 | +8.00% |
| 2016 (partial year) | −86.54% |
As of October 21, 2026.
CVM Revenue and Earnings by Fiscal Year
FY ends September| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$25.41M | — |
| 2024 | $0.00 | −$26.92M | — |
| 2023 | $0.00 | −$32.19M | — |
| 2022 | $0.00 | −$36.70M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$24.81M | −$25.41M | — |
| 2024 | $0.00 | — | −$26.35M | −$26.92M | — |
| 2023 | $0.00 | — | −$31.48M | −$32.19M | — |
| 2022 | $0.00 | — | −$36.06M | −$36.70M | — |
Annual figures as reported, in the company's reporting currency. As of September 30, 2025.
Recent News
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
YahooCEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY
BenzingaCEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B